Physician profile
Rui Cheng
NPI 1841679503
$7,183.29
in general payments reported to CMS, 2019-2025
25 companies · $691 in 2025
The $691 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,711 · 2020: $547 · 2021: $906 · 2022: $1,197 · 2023: $956 · 2024: $1,175 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,094.76 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $590.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $557.84 | 2019-2025 | Dupixent |
| Celgene Corporation | $461.37 | 2019 | |
| Sun Pharmaceutical Industries INC. | $375.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $346.00 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $340.98 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $295.49 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $271.94 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $269.80 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $230.92 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $202.99 | 2019-2025 | Adbry |
| Amgen INC. | $199.70 | 2019-2025 | Otezla |
| Dermavant Sciences, INC. | $149.39 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $135.45 | 2019-2024 | Cabtreo, Jublia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Incyte Corporation | $92.34 | 2022-2024 | Opzelura |
| Ucb, INC. | $85.57 | 2019-2024 | Bimzelx |
| Prugen, INC. Pharmaceuticals | $64.03 | 2019 | |
| Epi Health, LLC | $59.92 | 2022 | |
| Almirall LLC | $47.54 | 2022 | |
| Galderma Laboratories, L.P. | $46.46 | 2022-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.46 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $21.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rui Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.